iShares Core MSCI EAFE ETF vs State Street SPDR S&P Biotech ETF — how do they compare? iShares Core MSCI EAFE ETF trades at $101.04, while State Street SPDR S&P Biotech ETF trades at $159.13. Which is the better fit depends on your goals.
| IEFA | XBI | |
|---|---|---|
Sector | Broad Market / Factor | Broad Market / Factor |
52-Week High | $101.09 | $164.28 |
52-Week Low | $84.72 | $86.92 |
Signals from Pluang's Aura AI — not financial advice
IEFA trades at $100.895, up 0.36% today, with a bullish technical signal from moving averages and strong trend momentum indicated by ADX. The fund focuses on developed international markets excluding the U.S. and Canada, offering diversification benefits and a dividend yield of 3.30% as noted by The Motley Fool on June 13, 2026. Recent news highlights its cost efficiency compared to peers like EFA, with an expense ratio of 0.07%.
Outlook is positive due to defensive inflows and Fed cut potential, but risks include capped upside from covered call strategies and concentration in non-U.S. markets. Analyst sentiment is mixed, with some favoring broader ETFs like VXUS for higher returns.
XBI trades at $158.81, up 0.49% today, with a bullish technical signal supported by moving averages. The ETF shows strong momentum with a 17% monthly gain and 75% annual return, driven by biotech sector strength. Analyst coverage is limited to one hold rating, while recent news highlights institutional buying interest and positive sector developments including M&A activity and drug trial successes.
The outlook remains positive given biotech's breakout from multi-year bear markets, though elevated volatility and policy risks persist. Key opportunities include AI-driven drug discovery and sustained M&A momentum, while risks involve sector-specific volatility and regulatory uncertainty. The ETF's equal-weight approach provides diversified exposure to biotech innovation.
Trailing returns across standard periods
IEFA tracks the MSCI EAFE Investable Market Index, offering broad exposure to large, mid, and small-cap stocks in developed markets across Europe, Australasia, and the Far East. It serves as a low-cost core holding for international diversification, excluding the U.S. and Canada.
Read more on IEFA →XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →